|
Hormone
therapy doubled the risk of Alzheimer's disease and other types
of dementia in women who began the treatment at age 65 or older,
according to a large study.
The findings are the latest of a string of studies showing
that the supposed benefits of hormone therapy do not exist
and that the hormones actually raise the risk of several serious
disease.
The four-year study involved 4,532 women half of whom took
placebos, and half who took Prempro, which is a combination
of estrogen and progestin and the most widely prescribed type
of hormone therapy.
Forty cases of dementia developed in the hormone group during
the four years compared to 21 in the placebo group, leading
researchers to say that there’s no reason for older women
to take combination hormone therapy.
In terms of an annual rate, the findings indicate that for
every 10,000 women aged 65 years and older who take hormones,
45 cases of dementia will develop each year, 23 of them due
to the hormones.
Wyeth, Prempro’s manufacturer, plans to add a warning
to the drug’s label about the increased risk of dementia.
Researchers noted that the number of cases per year is small
and is no cause for alarm, but recommended that older women
who are taking combination hormone therapy should decide with
their doctors whether they should quit.
It is not known whether the findings apply to younger postmenopausal
women or women who take other hormone combinations or estrogen
alone.
Two other studies have found that combined hormone therapy
has a negative impact on the brain and increases the risk
of stroke.
Of
the 2.7 million American women who take combination hormone
therapy, 1.2 million use Prempro. The hormones were approved
by the Food and Drug Administration (FDA) to treat menopausal
symptoms like hot flashes and night sweats and to prevent
the bone-thinning disease osteoporosis.
However, the hormones slightly increase the risk of breast
cancer, strokes and heart attacks, so the agency recommends
that women consider other treatments for osteoporosis and
that they use the lowest dose of hormones for the shortest
time possible.
Last year a large study was halted after findings indicated
that the combination therapy caused a small but significant
increase in the risk of invasive breast cancer. Many women
stopped taking the hormones after the study came out--prior
to the study about 6 million women were taking combination
therapy.
However, many people still believed that the hormone therapy
might protect the brain and help prevent Alzheimer’s
disease.
The
theory that estrogen might prevent Alzheimer's was based on
earlier, survey-type studies suggesting that women on hormones
had lower rates of dementia than women not on hormones. But
those studies were not considered as reliable as the current
study because they were smaller and did not contain control
groups.
The current study suggests that any good effects the hormones
may have on brain cells may be offset by harmful effects.
Researchers are not certain how the combination therapy increases
the risk of dementia but suggested that it increased the risk
of blood clots and clogged blood vessels in the brain, which
might injure brain cells and contribute to Alzheimer’s
disease.
Numerous studies are being conducted to further assess the
impact of hormone therapy on diseases such as osteoporosis,
heart disease and Alzheimer's disease.
New
York Times May 28, 2003
|